## REMARKS

Applicants are filing this Amendment concurrently with a Response to the June 1, 2005 Restriction Requirement in which Applicants have elected the invention of Group I (claims 1-14) drawn to a polypeptide. Claims 15-22 have been cancelled without prejudice or disclaimer. Claim 5 has been amended. The amendment presented herein is fully supported by the specification and claims as originally filed. Accordingly, no new matter has been added by the present amendment.

## **CONCLUSION**

On the basis of the foregoing amendment and remarks, Applicants respectfully submit, that the pending claims are in condition for allowance. If there are any questions regarding this amendment and/or these remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,

Ingrid A. Beattie, Reg. No. 42,306

Attorney for Applicants c/o MINTZ, LEVIN One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241 Customer No. 30623

TRA 2097394v.1